StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Ocular Therapeutix's operating cash flow for the twelve months ending Jun 30, 2026 was -$238.24M. For fiscal 2025 it was -$204.88M. The highest annual figure on record is -$12.59M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$204.88M–
FY2024Dec 31, 2024-$134.68M–
FY2023Dec 31, 2023-$70.23M–
FY2022Dec 31, 2022-$59.60M–
FY2021Dec 31, 2021-$65.55M–
FY2020Dec 31, 2020-$53.55M–
FY2019Dec 31, 2019-$77.58M–
FY2018Dec 31, 2018-$49.23M–
FY2017Dec 31, 2017-$50.47M–
FY2016Dec 31, 2016-$34.00M–
FY2015Dec 31, 2015-$33.74M–
FY2014Dec 31, 2014-$20.50M–
FY2013Dec 31, 2013-$12.65M–
FY2012Dec 31, 2012-$12.59M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$67.27M–
Q1 FY2026Mar 31, 2026-$65.99M–
Q4 FY2025Dec 31, 2025-$54.25M–
Q3 FY2025Sep 30, 2025-$50.73M–
Q2 FY2025Jun 30, 2025-$55.24M–
Q1 FY2025Mar 31, 2025-$44.67M–
Q4 FY2024Dec 31, 2024-$39.43M–
Q3 FY2024Sep 30, 2024-$36.56M–
Q2 FY2024Jun 30, 2024-$24.80M–
Q1 FY2024Mar 31, 2024-$33.89M–
Q4 FY2023Dec 31, 2023-$22.45M–
Q3 FY2023Sep 30, 2023-$7.73M–
Q2 FY2023Jun 30, 2023-$20.08M–
Q1 FY2023Mar 31, 2023-$19.97M–
Q4 FY2022Dec 31, 2022-$16.96M–
Q3 FY2022Sep 30, 2022-$13.17M–
Q2 FY2022Jun 30, 2022-$10.88M–
Q1 FY2022Mar 31, 2022-$18.60M–
Q4 FY2021Dec 31, 2021-$15.15M–
Q3 FY2021Sep 30, 2021-$12.98M–
Q2 FY2021Jun 30, 2021-$20.06M–
Q1 FY2021Mar 31, 2021-$17.36M–
Q4 FY2020Dec 31, 2020-$6.25M–
Q3 FY2020Sep 30, 2020-$13.66M–
Q2 FY2020Jun 30, 2020-$14.80M–
Q1 FY2020Mar 31, 2020-$18.85M–
Q4 FY2019Dec 31, 2019-$19.47M–
Q3 FY2019Sep 30, 2019-$19.54M–
Q2 FY2019Jun 30, 2019-$19.18M–
Q1 FY2019Mar 31, 2019-$19.39M–
Q4 FY2018Dec 31, 2018-$13.65M–
Q3 FY2018Sep 30, 2018-$10.87M–
Q2 FY2018Jun 30, 2018-$12.23M–
Q1 FY2018Mar 31, 2018-$12.47M–
Q4 FY2017Dec 31, 2017-$10.38M–
Q3 FY2017Sep 30, 2017-$14.38M–
Q2 FY2017Jun 30, 2017-$11.13M–
Q1 FY2017Mar 31, 2017-$14.58M–
Q4 FY2016Dec 31, 2016-$7.61M–
Q3 FY2016Sep 30, 2016-$7.33M–

More Ocular Therapeutix figures

See a number that looks wrong?